SEPILIFT ™ DPHP

Triple firming action for

rejuvenation, moisturisation and
anti-age wrinkle prevention

3480/GB/01/February 2007 / 1
1 - Structure

3480/GB/01/February 2007 / 2
 SEPILIFT™ DPHP,
Anti-age ingredient : its structure

z Structure
Hydroxyproline Palmitic acid
Collagen-specific aminoacid
(biotechnological derived) (plant-derived)

Grafting

SEPILIFT
SEPILIFT™™ DPHP
DPHP

Hydroxyproline biovector
"wakes up" and rejuvenates the skin.

INCI name: Dipalmitoyl Hydroxyproline

3480/GB/01/February 2007 / 3
2 – In vivo anti-age efficacy

3480/GB/01/February 2007 / 4
 SEPILIFT ™ DPHP
FIRMING – MOISTURING AGENT

1. In vivo anti-aging ”curative” efficacy on crow’s feet

First study : 15 volunteers – 28 days of treatment - 1% Sepilift DPHP

(6767) – Study performed versus a placebo

Improvement of cutaneous micro-relief

Before treatment After 28 days of treatment by a formula

containing 1% SEPILIFT DPHP

Wrinkles corrector (deep and small)

(image analyser)
Moisture improvment : +18% in comparison to placebo
(corneometer)
3480/GB/01/February 2007 / 5
 SEPILIFT ™ DPHP,
Anti-ageing ingredient
2nd test : anti-aging efficacy versus a reference on the market (in vivo)
D42 : anti-age at high performance – Formula 7071
A • LANOL™ P (glycol palmitate – SEPPIC) 1.50 %
• MONTANOV TM 202 (Arachidyl alcohol & behenyl alcohol & arachidyl glucoside 2.00 %
- SEPPIC)
W
NE
• MONTANOV TM 82 (Cetearyl alcohol & Coco-glucoside - SEPPIC) 1.00 %
• Squalane 7.00 %
• Polyisobutene 13.00 %
• MONTANOX TM 60 DF (Polysornate 60 - SEPPIC)) 0.50 %
• Keltrol T 0.15 %
• SEPILIFT DPHP (Dipalmitoyl Hydroxyproline – SEPPIC) 1.00 %
B • Water Up to 100 %
• Chlorphenesin 0.30 %
• Glycerin 5.00 %
C • SEPIPLUS™ 400 (Polyacrylate-13 & polyisobutene & polysorbate 20 – SEPPIC) 1.00 %
D • SEPICIDE™ LD (Phenoxyethanol – SEPPIC) 0.70 %
• Fragrance 0.10 %
• TEA 50% Up to pH = 5.5

Method:
•In vivo: 20 volunteers (average age: 56 years)
•Efficacy of 1% SEPILIFT DPHP versus placebo and versus an anti-age lipopeptide
on the market (3%)
•2 applications/day
•42 days of treatment on crow’s feet
•Number of wrinkles: analysis software
Demonstrated efficacy in comparison to the placebo formula (same
formula without active ingredient) and a reference lipopeptide on the
market 3480/GB/01/February 2007 / 6
 SEPILIFT ™ DPHP,
Anti-ageing ingredient
z Anti-aging efficacy versus a reference on the market (in
vivo):
Efficacy of 1% SEPILIFT DPHP versus placebo and an anti-aging lipopeptide
on the market (3%) after 42 days of treatment
% reduction in Placebo
number of 0%
wrinkles After treatment, 65% of
-2%
volunteers having used
-4% No effect the formula with SEPILIFT
Lipopeptide 3% DPHP showed a positive
-6%
effect in comparison to
-8% placebo.
-10%
*: p<0.05
-12%
Lipopeptide = Glycerin and Water and
-32% * Butylene Glycol and Carbomer and
-14%
Polysorbate 20 and Palmitoyl Oligopeptide
-16% and Palmitoyl Tetrapeptide-7
SEPILIFT DPHP 1%

Only the formula with 1% SEPILIFT DPHP significantly reduces

the number of wrinkles in comparison to placebo.
No significant efficacy of the formula with 3% anti-ageing lipopeptide on
the market in comparison to placebo 3480/GB/01/February 2007 / 7
 SEPILIFT ™ DPHP
FIRMER - MOISTURIZER

B. On lips : 30 volunteers – 15 days of treatment - 1% Sepilift DPHP in a

lipstick (6831)

Improvement of immediate and long-term moisturisation (corneometer)

+ 15% 10 minutes after application
+ 10% after 15 days of treatment

Restructuring of labial mucuous after 15 days :

- 15 % of Trans Epidermal Water Loss (evaporimeter)

Anti wrinkle effect : -37% of the width and depth of lips’ furrows after
15 days (image analyser)

ƒ “Glamour” effect

Before application D15 After application D15

3480/GB/01/February 2007 / 8
3 – Mode of action

3480/GB/01/February 2007 / 9
 SEPILIFT™ DPHP against SKIN ALTERATIONS

COMPLETE ACTION ON DERMIS

WRINKLES CORRECTOR
& MOISTURIZER (Lips and Face) 1. Contraction of collagen fibers
+ 14% of collagen fibers contraction (0.001%
DPHP)

2. Protection of elastic fibers

+ 81% anti-elastase effect (0.05% DPHP)
Epidermis

3. Radical scavenging effect

+ 85% inhibition of superoxyde anion (0.07%
DPHP)

4. Stimulation of TIMPs, natural anti

age inhibitors
Dermis

+ 46% of TIMP2 stimulation by fibroblasts

(0.0005% DPHP)

5. Inhibition of MMPs, enzymes

responsible for skin’s ageing process
+ 94% of MMP2 inhibition by fibroblasts (0.0005%
DPHP)
Hypodermis

6. Protection of dermo epidermal

matrix and collagen
+26% of pro-collagen 1 stimulation by
fibroblasts (0.0005% DPHP), +61% of laminins
stimulation by fibroblasts (0.0005% DPHP)

3480/GB/01/February
C/1864/GB/01/ December 20012007 / 10
10
4 – Cosmetic applications

3480/GB/01/February 2007 / 11
 SEPILIFT ™ DPHP
FIRMER - MOISTURIZER

4. Very well tolerated, SEPILIFT DPHP can be incorporated at 1% in :

INDICATIONS COSMETICS APPLICATION

n Long lasting moisturization è Anti-wrinkle and anti-age
n Anti-wrinkle activity products
n Firming activity è Firming products
n Skin elasticity protection è Sliming products
n Radical scavenging effect è Anti-stretch mark products
n Stimulation of natural anti è Care products (body and face)
age defenses è Sun and after sun products
n Long lasting lipophilic è Make-up products (Lipsticks,
moisturizer foundations, powders …)
n Anti-wrinkles
n
n Stimulation des défenses
Texturizing agent
anti-age

3480/GB/01/February 2007 / 12
Nota

The analytical specifications warranted are only those mentioned on the certificate of analysis supplied with each delivery of the product.

Except as set forth above, SEPPIC* makes no warranties, whether express, implied or statutory, as to the product which is the subject of this document . Without
limiting the generality of the foregoing, SEPPIC* makes no warranty of merchantability of the product or of the fitness of the product for any particular purpose.
Buyer assumes all risk and liability resulting from the use or sale of the product, whether singly or in combination with other goods. The information set forth
herein is furnished free of charge and is based on technical data that SEPPIC* believes to be reliable. It is intended for use by persons having technical skill and at
their own discretion and risk. Since conditions of use are outside SEPPIC*'s control, SEPPIC* makes no warranties, express or implied, and assumes no liability in
connection with any use of this information. Nothing herein is to be taken as a license to operate under or a recommendation to infringe any patents.

* SEPPIC being: And, depending on the country:

SEPPIC S.A. SEPPIC UK Ltd SEPPIC ITALIA Srl

Tour Kupka C 50 Salisbury Road Via Quarenghi 27
7, boulevard Franck Kupka PO Box 338 - Hounslow 20151 Milano
92039 Paris La Défense Cedex TW4 6SH - ENGLAND ITALY
FRANCE
Tel. : +33 (0) 1 55 91 57 00 Tel. : +44 208 577 8800 Tel. : +39 02 38009110
Fax : +33 (0) 1 55 91 50 50 Fax : +44 208 570 2106 Fax : +39 02 38009140

GIVAUDAN LAVIROTTE S.A. SEPPIC Inc. SEPPIC China

56, rue Paul Cazeneuve 30, Two Bridges Road, suite 210 Room 510 Jin Tai Building
BP 8344 – 69008 Lyon Fairfield, New Jersey 07004-1530 58 South Mao Ming Road
FRANCE USA Shanghai 200020 CHINA
Tel. : +33 (0) 4 78 61 55 00 Tel. : +1 973 882 5597 Tel. : +86 (21) 64 66 01 49
Fax : +33(0) 4 72 05 60 89 Fax : +1 973 882 5178 Fax : +86 (21) 64 66 11 09

SEPPIC GmbH SEPPIC Belgium NV

ABC Tower Köln Nieuwe Weg 1
Ettore - Bugatti - Str.6-14 Haven 1053
51149 Köln-Porz B – 2070 Zwijndrecht
GERMANY BELGIUM
Tel. : +49 (0) 220 3890 3100 Tel. : +32 3 250 3911
Fax : +49 (0) 220 3890 3199 Fax : +32 3 250 3912

www.seppic.com

Subsidiary of the AIR LIQUIDE Group

3480/GB/01/February 2007 / 13